Olivia Carlson is a Senior Associate at F-Prime, focusing on investments in healthcare technology and services companies. Prior to joining F-Prime, she was an investor at M33 Growth, where she assessed investment opportunities and supported their portfolio of growth-stage healthcare companies. Olivia also worked in strategy consulting for EY-Parthenon’s healthcare team. She started her career as a certified nursing assistant, working for a home health and hospice company throughout college.
Olivia holds a B.A. from Williams College, where she majored in Pre-Medical Studies and Psychology.
Chance is an Associate at F-Prime, where he focuses on early-stage investments in enterprise software. Before joining F-Prime, he was a consultant in Accenture’s Software & Platforms Strategy practice, advising leading hyperscalers and technology companies on go-to-market, product, and market expansion strategies.
Chance holds a B.S. in Managerial Economics from the University of California, Davis.
Crissy Derome joined F-Prime Capital in 2024 and currently supports the Crypto team. She also serves as Project Coordinator for Fine Structure Ventures, where she manages executive operations, complex scheduling, and cross-functional initiatives with precision and discretion.
Before joining F-Prime, Crissy held senior administrative roles at Fidelity Investments and Devonshire Investors, supporting executives across Corporate Development, Fidelity Labs, and Asset Management. Earlier in her career, she spent over a decade at Shields Health Care Group, leading administrative operations and coordinating major corporate and philanthropic events.
She holds a degree in Paralegal Studies from Eastern Nazarene College and is a certified Notary Public in the Commonwealth of Massachusetts.
Tomesha Campbell joined F-Prime in September 2025 as an Executive Assistant to Stacie Weninger, PhD and Chong Xu, PhD. Prior to joining F-Prime, she worked as an Administrative Assistant for Harvard Management Company, where she supported the finance, operations, and investment teams.
Tomesha earned her BA from Albright College and holds a dual MA from The Heller School at Brandeis University.
Tenzin Jampa joined F-Prime in 2025 as a data scientist, where he focuses on data science and automation. Tenzin graduated from MIT in 2025. During his time at MIT, he conducted research at the Laboratory for Nuclear Science, worked on analyzing the early data samples from the 2024 LHCb Run, and evaluated Large Language Models for physics domain specialization. Tenzin enjoys writing and occasionally publishes on his blog. In his free time, he loves to watch or play soccer, go on walks, play video games, or read.
Tenzin holds a B.S. degree from MIT in Physics and Philosophy.
Eric joined F-Prime in 2021 as a Venture Partner focused on executive leadership and go-to-market functions in technology and cybersecurity companies. Eric has founded and helped lead organizations from startup to $100 million plus revenue, including RiskRecon (acquired by Mastercard), Trusteer (acquired by IBM), Imprivata (IPO), and Centra Software (IPO).
Eric earned his undergraduate degree from Wharton School of University of Pennsylvania and his MBA from MIT Sloan School of Management.
Dr. Namandjé N. Bumpus joined F-Prime in 2025, where she serves as a strategic advisor on regulatory science, regulatory affairs, and policy, bringing deep expertise from her previous roles as FDA Principal Deputy Commissioner and Chief Scientist. Before the FDA, Dr. Bumpus was the E.K. Marshall and Thomas H. Maren Professor and director of the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine, where her research advanced understanding of drug metabolism, mechanisms of drug-induced toxicity, pharmacogenetics, bioanalytical chemistry, infectious disease pharmacology, and single cell biology. She completed her postdoctoral fellowship at The Scripps Research Institute and holds a PhD in pharmacology from the University of Michigan and a bachelor’s degree in biology from Occidental College.
Dr. Bumpus is a past-president of the American Society for Pharmacology and Experimental Therapeutics, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine.
Claire Knowlton joined F-Prime in 2025 as a Marketing Associate. Claire supports marketing initiatives through event planning and internal communications. Previously, she worked at an estate planning law firm, focusing on email and social media marketing.
Claire holds a BA in Marketing from Loyola University Chicago.
Abby Wagner joined F-Prime in September 2024, and currently holds a Senior Accountant role. She previously held an Assurance Senior position at Ernst & Young, LLP serving primarily private clients in the wealth and asset management industry.
Abby earned an MBA and BS in Accounting with a Minor in Finance from Auburn University.
Clare Bernard is a Venture Partner at F-Prime. She is focused on new company creation at the intersection of tech and the life sciences. Prior to F-Prime she led data science and software efforts at the Broad Institute, managing the team that developed several widely used open-source bioinformatics tools and software platforms including the Terra platform and GATK. She also led product and engineering at Tamr, a Cambridge-based software company that uses machine learning to integrate large datasets.
She received her B. in math and physics from Johns Hopkins University and her PhD from Boston University for research in particle physics conducted at the Large Hadron Collider.